Health Care & Life Sciences » Pharmaceuticals | AstraZeneca PLC

AstraZeneca PLC | Income Statement

Fiscal year is January-December. All values GBP Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
16,449
16,123
16,172
17,047
17,444
16,567
Cost of Goods Sold (COGS) incl. D&A
4,102
4,505
3,986
4,129
4,517
4,675
Gross Income
12,347
11,618
12,186
12,919
12,927
11,891
SG&A Expense
8,394
9,499
9,842
10,278
10,232
10,514
EBIT
3,938
-
-
2,641
2,695
1,377
Unusual Expense
2,061
1,583
1,111
837
1,655
835
Non Operating Income/Expense
456
330
1,020
1,278
1,193
1,522
Interest Expense
264
254
257
457
516
556
Pretax Income
2,090
760
2,019
2,657
1,772
1,579
Income Tax
445
7
159
108
498
43
Equity in Affiliates
-
4
10
24
43
85
Consolidated Net Income
1,645
750
1,850
2,524
2,227
1,537
Net Income
1,635
749
1,849
2,593
2,330
1,616
Net Income After Extraordinaries
1,635
749
1,849
2,593
2,330
1,616
Net Income Available to Common
1,635
749
1,849
2,593
2,330
1,616
EPS (Basic)
1.31
1.61
3.41
2.05
1.84
1.28
Basic Shares Outstanding
1,252
1,262
1,264
1,265
1,266
1,267
EPS (Diluted)
1.30
0.59
1.46
2.05
1.84
1.28
Diluted Shares Outstanding
1,254
1,264
1,265
1,266
1,267
1,267
EBITDA
5,656
4,167
4,095
4,353
4,600
3,461
Other Operating Expense
14
129
-
-
-
-
Non-Operating Interest Income
20
20
24
32
54
72
Minority Interest Expense
10
1
1
69
103
79

About AstraZeneca

View Profile
Address
Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA
United Kingdom
Employees -
Website http://astrazeneca.com
Updated 07/08/2019
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 0382, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.